Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization

Mihaela Necula, Leonid Breydo, Saskia Milton, Rakez Kayed, Wytze E. Van Der Veer, Paul Tone, Charles G. Glabe

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Amyloid plaques are hallmark neuropathological lesions in Alzheimer's disease, which consist of abnormally aggregated Aβ protein. Multiple Aβ aggregated species have been identified, and neurotoxicity appears to be correlated with the amount of nonfibrillar oligomers. Therefore, selective inhibition of Aβ oligomer formation has emerged as an attractive means of therapeutic intervention. To investigate whether small molecules can modulate aggregation to achieve selective inhibition of neurotoxic amyloid oligomers, Aβ aggregation was assayed in vitro in the presence of methylene blue, using immunoreactivity with the prefibrillar oligomer-specific antibody A11, transmission electron microscopy, and turbidity assays. Methylene blue inhibited oligomerization when used at substoichiometric concentrations relative to that of the Aβ monomer. Inhibition of Aβ oligomerization was achieved concomitant with promotion of fibrillization, suggesting that oligomer and fibril formation are distinct and competing pathways. Methylene blue-mediated promotion of fiber formation occurred via a dose-dependent decrease in the lag time and an increase in the fibrillization rate, consistent with promotion of both filament nucleation and elongation. Addition of methylene blue to preformed oligomers resulted in oligomer loss and promotion of fibrillization. The data show that Aβ oligomer formation is inhibited by promoting fibril formation, which suggests that the relative pathological significance of oligomers and fibrils may be tested in vivo using methylene blue. If Aβ oligomers represent the primary pathogenic species, then inhibition of this highly toxic species via promotion of formation of less toxic aggregates may be therapeutically useful.

Original languageEnglish (US)
Pages (from-to)8850-8860
Number of pages11
JournalBiochemistry
Volume46
Issue number30
DOIs
StatePublished - Jul 31 2007
Externally publishedYes

Fingerprint

Oligomerization
Methylene Blue
Oligomers
Amyloid
Poisons
Amyloid Plaques
Transmission Electron Microscopy
Alzheimer Disease
Agglomeration
Inhibition (Psychology)
Antibodies
Turbidity
Elongation
Assays
Proteins
Nucleation
Monomers
Transmission electron microscopy

ASJC Scopus subject areas

  • Biochemistry

Cite this

Necula, M., Breydo, L., Milton, S., Kayed, R., Van Der Veer, W. E., Tone, P., & Glabe, C. G. (2007). Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization. Biochemistry, 46(30), 8850-8860. https://doi.org/10.1021/bi700411k

Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization. / Necula, Mihaela; Breydo, Leonid; Milton, Saskia; Kayed, Rakez; Van Der Veer, Wytze E.; Tone, Paul; Glabe, Charles G.

In: Biochemistry, Vol. 46, No. 30, 31.07.2007, p. 8850-8860.

Research output: Contribution to journalArticle

Necula, M, Breydo, L, Milton, S, Kayed, R, Van Der Veer, WE, Tone, P & Glabe, CG 2007, 'Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization', Biochemistry, vol. 46, no. 30, pp. 8850-8860. https://doi.org/10.1021/bi700411k
Necula M, Breydo L, Milton S, Kayed R, Van Der Veer WE, Tone P et al. Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization. Biochemistry. 2007 Jul 31;46(30):8850-8860. https://doi.org/10.1021/bi700411k
Necula, Mihaela ; Breydo, Leonid ; Milton, Saskia ; Kayed, Rakez ; Van Der Veer, Wytze E. ; Tone, Paul ; Glabe, Charles G. / Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization. In: Biochemistry. 2007 ; Vol. 46, No. 30. pp. 8850-8860.
@article{63756afb8e064a2da29b1d6b73d9585c,
title = "Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization",
abstract = "Amyloid plaques are hallmark neuropathological lesions in Alzheimer's disease, which consist of abnormally aggregated Aβ protein. Multiple Aβ aggregated species have been identified, and neurotoxicity appears to be correlated with the amount of nonfibrillar oligomers. Therefore, selective inhibition of Aβ oligomer formation has emerged as an attractive means of therapeutic intervention. To investigate whether small molecules can modulate aggregation to achieve selective inhibition of neurotoxic amyloid oligomers, Aβ aggregation was assayed in vitro in the presence of methylene blue, using immunoreactivity with the prefibrillar oligomer-specific antibody A11, transmission electron microscopy, and turbidity assays. Methylene blue inhibited oligomerization when used at substoichiometric concentrations relative to that of the Aβ monomer. Inhibition of Aβ oligomerization was achieved concomitant with promotion of fibrillization, suggesting that oligomer and fibril formation are distinct and competing pathways. Methylene blue-mediated promotion of fiber formation occurred via a dose-dependent decrease in the lag time and an increase in the fibrillization rate, consistent with promotion of both filament nucleation and elongation. Addition of methylene blue to preformed oligomers resulted in oligomer loss and promotion of fibrillization. The data show that Aβ oligomer formation is inhibited by promoting fibril formation, which suggests that the relative pathological significance of oligomers and fibrils may be tested in vivo using methylene blue. If Aβ oligomers represent the primary pathogenic species, then inhibition of this highly toxic species via promotion of formation of less toxic aggregates may be therapeutically useful.",
author = "Mihaela Necula and Leonid Breydo and Saskia Milton and Rakez Kayed and {Van Der Veer}, {Wytze E.} and Paul Tone and Glabe, {Charles G.}",
year = "2007",
month = "7",
day = "31",
doi = "10.1021/bi700411k",
language = "English (US)",
volume = "46",
pages = "8850--8860",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "30",

}

TY - JOUR

T1 - Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization

AU - Necula, Mihaela

AU - Breydo, Leonid

AU - Milton, Saskia

AU - Kayed, Rakez

AU - Van Der Veer, Wytze E.

AU - Tone, Paul

AU - Glabe, Charles G.

PY - 2007/7/31

Y1 - 2007/7/31

N2 - Amyloid plaques are hallmark neuropathological lesions in Alzheimer's disease, which consist of abnormally aggregated Aβ protein. Multiple Aβ aggregated species have been identified, and neurotoxicity appears to be correlated with the amount of nonfibrillar oligomers. Therefore, selective inhibition of Aβ oligomer formation has emerged as an attractive means of therapeutic intervention. To investigate whether small molecules can modulate aggregation to achieve selective inhibition of neurotoxic amyloid oligomers, Aβ aggregation was assayed in vitro in the presence of methylene blue, using immunoreactivity with the prefibrillar oligomer-specific antibody A11, transmission electron microscopy, and turbidity assays. Methylene blue inhibited oligomerization when used at substoichiometric concentrations relative to that of the Aβ monomer. Inhibition of Aβ oligomerization was achieved concomitant with promotion of fibrillization, suggesting that oligomer and fibril formation are distinct and competing pathways. Methylene blue-mediated promotion of fiber formation occurred via a dose-dependent decrease in the lag time and an increase in the fibrillization rate, consistent with promotion of both filament nucleation and elongation. Addition of methylene blue to preformed oligomers resulted in oligomer loss and promotion of fibrillization. The data show that Aβ oligomer formation is inhibited by promoting fibril formation, which suggests that the relative pathological significance of oligomers and fibrils may be tested in vivo using methylene blue. If Aβ oligomers represent the primary pathogenic species, then inhibition of this highly toxic species via promotion of formation of less toxic aggregates may be therapeutically useful.

AB - Amyloid plaques are hallmark neuropathological lesions in Alzheimer's disease, which consist of abnormally aggregated Aβ protein. Multiple Aβ aggregated species have been identified, and neurotoxicity appears to be correlated with the amount of nonfibrillar oligomers. Therefore, selective inhibition of Aβ oligomer formation has emerged as an attractive means of therapeutic intervention. To investigate whether small molecules can modulate aggregation to achieve selective inhibition of neurotoxic amyloid oligomers, Aβ aggregation was assayed in vitro in the presence of methylene blue, using immunoreactivity with the prefibrillar oligomer-specific antibody A11, transmission electron microscopy, and turbidity assays. Methylene blue inhibited oligomerization when used at substoichiometric concentrations relative to that of the Aβ monomer. Inhibition of Aβ oligomerization was achieved concomitant with promotion of fibrillization, suggesting that oligomer and fibril formation are distinct and competing pathways. Methylene blue-mediated promotion of fiber formation occurred via a dose-dependent decrease in the lag time and an increase in the fibrillization rate, consistent with promotion of both filament nucleation and elongation. Addition of methylene blue to preformed oligomers resulted in oligomer loss and promotion of fibrillization. The data show that Aβ oligomer formation is inhibited by promoting fibril formation, which suggests that the relative pathological significance of oligomers and fibrils may be tested in vivo using methylene blue. If Aβ oligomers represent the primary pathogenic species, then inhibition of this highly toxic species via promotion of formation of less toxic aggregates may be therapeutically useful.

UR - http://www.scopus.com/inward/record.url?scp=34547672881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547672881&partnerID=8YFLogxK

U2 - 10.1021/bi700411k

DO - 10.1021/bi700411k

M3 - Article

C2 - 17595112

AN - SCOPUS:34547672881

VL - 46

SP - 8850

EP - 8860

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 30

ER -